Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TZ-POR 7f is a potent and selective small-molecule inhibitor of **Cytochrome P450 oxidoreductase (POR)**, characterized by a triazole-based scaffold. POR is a critical diflavin enzyme that serves as the obligatory electron donor for all microsomal cytochrome P450 (CYP) enzymes, as well as other redox partners like heme oxygenase and squalene monooxygenase. TZ-POR 7f was developed as a chemical tool to investigate the role of POR in drug metabolism and the activation of **hypoxia-activated prodrugs (HAPs)**, such as evofosfamide and tirapazamine. By binding to POR and disrupting the electron transport chain from NADPH to its redox partners, TZ-POR 7f effectively suppresses POR-dependent enzymatic activities. This inhibition can be used to modulate CYP-mediated drug metabolism or to prevent the off-target reductive activation of HAPs in normoxic tissues, potentially reducing systemic toxicity in cancer therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TZ-POR 7f.